Graceway Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Bristol TN United States (2006)
Status: Acquired by Medicis (2011) → now Bausch Health Companies (2012)

Organization Overview

First Clinical Trial
2006
NCT00189306
First Marketed Drug
2011
imiquimod (aldara)
First NDA Approval
None
Last Known Activity
2011

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

GRACEWAY | Graceway Pharmaceuticals, LLC

Active Ingredients

Marketed Drugs (1)

Key: Graceway (0) Acquired (1)

imiquimod (aldara) (2011)

Drugs in Phase 4 Trials (9)

Key: Graceway (1) Acquired (8)

chlorhexidine (hibitane) (13 trials)

ethanol (2 trials)

flecainide (tambocor) (1 trial)

imiquimod (aldara) (21 trials)

iodine (2 trials)

isopropyl alcohol (10 trials)

methylene blue (proveblue) (1 trial)

mupirocin (bactroban) (1 trial)

povidone-iodine (4 trials)

Drugs in Phase 3 Trials (6)

Key: Graceway (0) Acquired (6)

budesonide (rhinocort) (1 trial)

cavilon (1 trial)

formoterol (foradil) (1 trial)

sodium chloride (4 trials)

sorbolene (1 trial)

symbicort (1 trial)

Drugs in Phase 2 Trials (3)

metronidazole (flagyl) (1 trial)

petrolatum, white (Vaseline) (1 trial)

resiquimod (6 trials)

Drugs in Phase 1 Trials (3)

Key: Graceway (0) Acquired (3)

fluticasone (cutivate) (1 trial)

salmeterol (serevent) (1 trial)

tiotropium (spiriva) (5 trials)

Drugs in Other Trials (3)

Key: Graceway (0) Acquired (3)

iodine povacrylex (1 trial)

pf-04878691 (1 trial)

sodium lauryl sulfate (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 3)

Carcinoma, Basal Cell (Phase 3)

Condylomata Acuminata (Phase 3)

Hemangioma (Phase 2)

Hemangioma, Capillary (Phase 2)

Keratosis (Phase 4)

Keratosis, Actinic (Phase 4)

Port-Wine Stain (Phase 2)

Recurrence (Phase 3)

Vaginal Diseases (Phase 2)

Vaginosis, Bacterial (Phase 2)

Warts (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 57
  • # of Trial APIs: 24